There's never a sure thing when it comes to decisions from the Food and Drug Administration, but when it comes to Cornerstone Therapeutics' (NASDAQ: CRTX) drug Lixivaptan, investors have all but conceded that a complete response letter (read: rejection) is in the cards.
In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss why the outlook is so gloomy for this drug, and how one company is looking particularly smart for cutting ties with the drug two years ago.
